세계의 이 치료 시장(2023-2030년)

Overview

Global Lice Treatment Market reached US$ 0.1 billion in 2022 and is expected to reach US$ 0.2 billion by 2030, growing with a CAGR of 6.3% during the forecast period 2023-2030.

Lice are typically transmitted from child to child through sharing clothing, hats, scarves, combs, brushes, hair trims, or helmets with nits. They can also be passed during contact sports. Head lice lay small white eggs at the base of hair near the scalp, particularly on the back of the neck and behind the ears.

After treatment, the infected person should be checked by another person for lice and nits using a magnifying glass and bright light. Treatment is usually recommended for persons diagnosed with an active infestation, including all household members and close contacts. Prophylactic treatment is advised for those sharing the same bed with actively-infested individuals. All infested persons and their bedmates should be treated simultaneously. Supplemental measures can be combined with pharmacologic treatment, but these are generally not required to eliminate a head lice infestation.

Furthermore, the global lice treatment is driven by various factors like, rising investment for the development of advanced technologies, an increase in the number of emerging markets, a rise in research and development, advancements in treatment options having significant key players like Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc, Johnson & Johnson Private Limited and among others.

Dynamics

Rise in the Prevalence of Lice Infestation

The rise in the prevalence of lice infestation is one of the factors to drive the market during the forecast period. Infestation with head lice (Pediculosis capitis) is a common health problem, it is an infectious condition caused by an obligatory ectoparasite, the human louse (Pediculus humanus capitis) and affects only the human scalp.

For instance, according to the article published by Health Equity in the National Library of Medicine, the prevalence of head lice in poor rural communities and urban slums is estimated to be between 28% and 43% in Brazil, respectively. Children are among the most affected, often in clusters within schools. We launched a program intending to tackle the social stigma associated with head lice using scientific information and a local traditional remedy as a way to lower the prevalence of head lice in a low-resource community.

Rise in Product Approvals by Regulatory Authorities

Product approvals by regulatory authorities play an important role in the lice treatment market as lice treatment products required regulatory approvals to check efficacy, quality and labelling. Hence the increasing product approvals by regulatory agencies of respective countries can drive the growth of the global lice treatment market. For instance, in April 2022, Arbor Pharmaceuticals Inc. (A subsidiary of Azurity Pharmaceuticals, Inc.), issued patents in the U.S. and Canada for its novel hair care technology containing all-natural ingredients to dislodge and safely remove lice and eggs from the hair shaft and scalp.

Increase in The Product Launches

Innovation of new products plays an important role to drive this market during the forecast period, as introducing new products creates improved formulations and fast delivery mechanisms which helps in the treatment have fewer complications. For instance, on June 21, 2023, Chosen by Dermatology- an India-based manufacturer of hair and scalp treatments, launched Child's Play, a hair serum with high plant content. The product can be used as a wash-off product when used to treat lice and nits.

Rise in the Population of Children Is Another Factor Supporting the Lice Treatment Market Share Growth

The rising number of children across the globe is expected to raise the demand for lice treatment solutions during the forecast period. Children are more prone to lice infestation as compared to adults, as they are less protective of their personal space and hygiene. There is a rapid rise in population across the globe; hence, the rising number of children is expected to propel market growth during the forecast period. The rising prevalence of lice infestation is also significantly high in children from nomad tribes, as compared to rural and urban areas due to lack of hygiene and awareness regarding lice infestation.

Side Effects Associated With Lice Treatment

Complications of lice treatments are one of the restraints that hamper the market from growth during the forecast period. Some of them are like Scalp irritation, including itching, swelling, or redness may occur with head lice and temporarily worsen after treatment with permethrin.

Also, A lack of awareness among people is expected to hamper the growth of the global lice treatment market. For instance, the lack of awareness of families about treating head lice often leads to the direct use of traditional medicines, including insecticides or kerosene, which can be very harmful and ultimately cause the death of the person being treated.

Segment Analysis

The global lice treatment market is segmented based on type, medication, distribution channel and region.

The Permethrin Segment From The Medication Segment Accounted for Approximately 41.7% of the Lice Treatment Share

The permethrin segment from the medication segment accounted for 41.7% and it is expected to be dominated during the forecast period. Permethrin treats scabies in adults and children two months of age and older. Over-the-counter permethrin is used to treat head lice (tiny insects that attach to the skin on the head) in adults and children two months of age and older. Permethrin is part of a group of medicines called scabies and Insecticides. It's effective in killing lice and mites.

Furthermore, according to NCBI in May 2022, permethrin is a common first-line treatment option for head lice infestations, which is available over the counter in many countries and a systematic review of trials that evaluated medications for the treatment of head lice suggested that permethrin was very much effective.

Also, the hospitals and clinics segment is expected to dominate during the forecast period. For instance, in August 2023 Hairline International Hair and Skin Clinic opened India's first-ever LICE Clinic to combat Head Lice Infestation. Head lice, a common concern among parents and children, can cause scalp itching and potential bacterial infections if left untreated. This can cause distress for affected individuals and parents.

Geographical Penetration

North America Accounted for Approximately 38.6% of the Market Share

North America is estimated to hold about 38.6% of the total market share throughout the forecast period, owing to the high prevalence of lice infestations among children, Product Innovation, advanced healthcare infrastructure, and rise in demand for chemical-free products, moreover, this region is having advanced technologies compared to another region which indeed helps this region to grow during the forecast period.

For instance, in August 2021 ParaPRO, a specialty pharmaceutical company, announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, the first new drug application for scabies approved by the FDA in over 30 years. The product is the first targeted topical treatment for scabies infestations in adult and pediatric patients aged four and older.

Competitive Landscape

The major global players in the market include: Alliance Pharmaceuticals, Omega Pharma(Perrigo Company), Prestige Brands Holdings Inc., Johnson & Johnson Private Limited, Fleming Medical Ltd, RID Lice(Oystershell Consumer Health, Inc) Nisarg Pharma, ParaPRO Pharmaceuticals, ICB Pharma, Marico and among others.

COVID-19 Impact Analysis

COVID-19 pandemic had numerous impacts on the lice treatment market where the spread of head lice infestations among the tested groups of children was more. However, it remains unclear whether factors such as the separation of children into smaller groups or increased parental attention during lockdown contributed to the reduction in infestation rates compared to the period before the COVID-19 outbreak.

Thus, although COVID-19 has led to a shortage of essentials and created some hindrances, lice treatment has played an important role during COVID-19. Thus, the COVID-19 pandemic has impacted the growth of the studied market in the initial phase, however, currently; it is expected to have steady growth during the forecast period.

By Type

• Pediculosis Capitis
• Pediculosis Corporis
• Pediculosis Pubis

By Medication

• OTC Medication
  • Permethrin
  • Pyrethrin
  • Other Product Types

• Prescription Medication
  • Ivermectin
  • Spinosad
  • Malathion
  • By Distribution Channel

• Hospitals and Clinics
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In October 2022, Alliance Pharmaceuticals collaborated with South Florida Family Health and Research Centers and posted a clinical trial on clinicaltrials.gov to check the safety and efficacy of Vamousse Spray 'n' Go, compared to a 1% Permethrin control shampoo, in the treatment of head lice.
• In September 2022, the American Academy of Pediatrics updated guidance on diagnosing and treating head lice. New medications for treatment were also mentioned and they provided an algorithm for the management of affected patients and further provided clarification on diagnosis and treatment.
• In October 2021, Lice Clinics of America announced that the company completed 750,000 successful head lice treatments using heated air, with a very high success rate.

Why Purchase the Report?

• To visualize the global lice treatment market segmentation based on type, medication, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global lice treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lice treatment market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Medication
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Lice Infestation
    • 4.1.1.2. Rise in Product Approvals by Regulatory Authorities
    • 4.1.1.3. Increase in The Product Launches
    • 4.1.1.4. The Growing Population of Children Is Another Factor Supporting the Lice Treatment Market Share Growth.
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects Associated with Lice Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Rise in Research and Development
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Pediculosis Capitis *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Pediculosis Corporis
• 7.4. Pediculosis Pubis

8. By Medication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
  • 8.1.2. Market Attractiveness Index, By Medication
• 8.2. OTC Medications *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Prescription Medications

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospitals and Clinics *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Russia
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Alliance Pharmaceuticals*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Omega Pharma(Perrigo Company)
• 12.3. Prestige Brands Holdings Inc.
• 12.4. Johnson & Johnson Private Limited
• 12.5. Fleming Medical Ltd
• 12.6. RID Lice(Oystershell Consumer Health, Inc)
• 12.7. Nisarg Pharma
• 12.8. ParaPRO Pharmaceuticals
• 12.9. ICB Pharma
• 12.10. Marico

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us